BioCentury | Feb 5, 2021
Management Tracks

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

...pipeline robust enough to carry the pharma over Keytruda’s coming patent cliff. Chairman and CEO Ken Frazier...
...30 and hand over the reins to Davis, who is EVP, global services and CFO. Frazier...
...months following the announcement in October that Roger Perlmutter was retiring.During the early years of Frazier’s...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...acquisition by Novartis AG (NYSE:NVS; SIX:NOVN). She is the first U.S. hire for the Belgian company.Frazier...
...investment opportunities and creates new ventures. Nowicki identifies new public and private investment opportunities. BC Staff Arcutis Editas Medicine PRECIRIX frazier...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...Clancy, who was a senior adviser at Frazier...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...platforms.Frazier takes 50% stake in cold chain shipping companyPE firm Thomas H. Lee Partners granted Frazier...
BioCentury | Dec 4, 2020
Politics, Policy & Law

Trade groups move to derail rule that would tie drug prices with those in other countries

...Chairman and CEO Kenneth Frazier. In 2017, Frazier...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...in series C financing led by Farallon Capital Management LLC. Existing investors Blackstone Life Sciences, Frazier...
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...Ventures and Wu Capital joined existing investors Frazier...
...the round.Inipharm Inc. is reflective of how Frazier...
...firm’s success with Mavupharma Inc. That said, Frazier’s...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...Clancy, who was a senior adviser at Frazier...
BioCentury | Oct 14, 2020
Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

...round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.Frazier...
...and preclinical functions, clinical pharmacology and the scientific arm of BD. Jeff Cranmer Dewpoint Therapeutics Inozyme Pharma Inc. ReCode Therapeutics Frazier...
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...health organization of Johnson & Johnson (NYSE:JNJ); Annette Clancy, who was a senior adviser at Frazier...
Items per page:
1 - 10 of 460
BioCentury | Feb 5, 2021
Management Tracks

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

...pipeline robust enough to carry the pharma over Keytruda’s coming patent cliff. Chairman and CEO Ken Frazier...
...30 and hand over the reins to Davis, who is EVP, global services and CFO. Frazier...
...months following the announcement in October that Roger Perlmutter was retiring.During the early years of Frazier’s...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...acquisition by Novartis AG (NYSE:NVS; SIX:NOVN). She is the first U.S. hire for the Belgian company.Frazier...
...investment opportunities and creates new ventures. Nowicki identifies new public and private investment opportunities. BC Staff Arcutis Editas Medicine PRECIRIX frazier...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...Clancy, who was a senior adviser at Frazier...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...platforms.Frazier takes 50% stake in cold chain shipping companyPE firm Thomas H. Lee Partners granted Frazier...
BioCentury | Dec 4, 2020
Politics, Policy & Law

Trade groups move to derail rule that would tie drug prices with those in other countries

...Chairman and CEO Kenneth Frazier. In 2017, Frazier...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...in series C financing led by Farallon Capital Management LLC. Existing investors Blackstone Life Sciences, Frazier...
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...Ventures and Wu Capital joined existing investors Frazier...
...the round.Inipharm Inc. is reflective of how Frazier...
...firm’s success with Mavupharma Inc. That said, Frazier’s...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...Clancy, who was a senior adviser at Frazier...
BioCentury | Oct 14, 2020
Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

...round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology.Frazier...
...and preclinical functions, clinical pharmacology and the scientific arm of BD. Jeff Cranmer Dewpoint Therapeutics Inozyme Pharma Inc. ReCode Therapeutics Frazier...
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...health organization of Johnson & Johnson (NYSE:JNJ); Annette Clancy, who was a senior adviser at Frazier...
Items per page:
1 - 10 of 460